GlassScriptPhysician profile
Chalese Nelson
NPI 1548923543
$1,031.70
in general payments reported to CMS, 2019-2025
14 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $296 · 2024: $257 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,031.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $560.21 | 2023-2025 | |
| Madrigal Pharmaceuticals | $163.67 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $48.71 | 2024-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $44.42 | 2023-2024 | Flumist Quadrivalent |
| Pfizer INC. | $43.96 | 2023-2024 | |
| Alkermes, INC. | $39.51 | 2023-2024 | Vivitrol, Vivitrol |
| Dexcom, INC. | $18.54 | 2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $18.34 | 2024 | Gvoke Hypopen |
| Paratek Pharmaceuticals, INC. | $17.96 | 2023 | Nuzyra |
| Supernus Pharmaceuticals, INC. | $16.86 | 2025 | Qelbree |
| Averitas Pharma INC. | $16.40 | 2025 | Qutenza |
| Organon LLC | $14.65 | 2023 | Nexplanon |
| Merck Sharp & Dohme LLC | $14.28 | 2023 | Vaxneuvance, Vaxelis, Rotateq |
| Teva Pharmaceuticals USA, INC. | $14.19 | 2025 | Uzedy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chalese Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.